http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3259266-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 |
filingDate | 2016-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb71e0a319c04b93d66512d7c0ac7ce0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d62015b87f36fe69e590716963444cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_803836ca1ebf2fe38c918d74a6ccfc05 |
publicationDate | 2017-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-3259266-A1 |
titleOfInvention | Pyrazole compounds |
abstract | This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (MetAP2) and dipeptidyl peptidase-4 (DPP-4). MetAP2 is a metalloproteinase that cleaves initiator methionine from nascent peptide emerging from the ribosomes. WO 2010/065879 reports small molecule MetAP2 inhibitors for obesity treatment. DPP-4 inhibitors are an established drug class to improve glycemic control in patients with type 2 diabetes mellitus. Compounds with dual inhibitory activity in both MetAP2 and DPP-4 are desired. The present invention provides novel compounds with dual MetAP2 and DPP-4 inhibitition. These dual inhibitor compounds can be useful in the treatment of a MetAP2 and DPP-4 mediated condition. The present invention provides a compound of the following Formula (I); or a pharmaceutically acceptable salt thereof. In an embodiment of the invention, the compound is |
priorityDate | 2015-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.